CCNE1 and prostate cancer: To identify the possibility of targeting prostate cancer with OTUB1/Cyclin E1 axis, we treated PC3 cell with RO-3306, a Cyclin E1/CDK2 related inhibitor, in the range dose of 0, 340 nM, 1 uM, 2 uM, 3 uM, and 5 uM.